Composite Inflammatory Score for Predicting Progression‐Free Survival in Metastatic Clear Cell Renal Cell Carcinoma Treated With First‐Line Toripalimab Plus Axitinib
Yun‐Feng Wu,
Jing‐Suo Wang,
Chuan‐Ao Zhang,
Fan Zhang,
Zhi‐Yu Zhang
Wiley ·
2026-10-22
· DOI 10.1002/kjm2.70307
The publisher did not provide an abstract — full text is available via the link below.
Yun‐Feng Wu, Jing‐Suo Wang, Chuan‐Ao Zhang, Fan Zhang, Zhi‐Yu Zhang. Composite Inflammatory Score for Predicting Progression‐Free Survival in Metastatic Clear Cell Renal Cell Carcinoma Treated With First‐Line Toripalimab Plus Axitinib. // Kaohsiung Journal of Medical Sciences. – 2026. – DOI: 10.1002/kjm2.70307. – URL: https://onlinelibrary.wiley.com/doi/10.1002/kjm2.70307?af=R
Yun‐Feng Wu, Jing‐Suo Wang, Chuan‐Ao Zhang, Fan Zhang, & Zhi‐Yu Zhang (2026). Composite Inflammatory Score for Predicting Progression‐Free Survival in Metastatic Clear Cell Renal Cell Carcinoma Treated With First‐Line Toripalimab Plus Axitinib. Kaohsiung Journal of Medical Sciences. https://doi.org/10.1002/kjm2.70307
Yun‐Feng Wu, et al. “Composite Inflammatory Score for Predicting Progression‐Free Survival in Metastatic Clear Cell Renal Cell Carcinoma Treated With First‐Line Toripalimab Plus Axitinib.” Kaohsiung Journal of Medical Sciences, 2026. doi:10.1002/kjm2.70307.
@article{Wu2026,
title = {Composite Inflammatory Score for Predicting Progression‐Free Survival in Metastatic Clear Cell Renal Cell Carcinoma Treated With First‐Line Toripalimab Plus Axitinib},
author = {Wu, Yun‐Feng and Wang, Jing‐Suo and Zhang, Chuan‐Ao and Zhang, Fan and Zhang, Zhi‐Yu},
journal = {Kaohsiung Journal of Medical Sciences},
year = {2026},
doi = {10.1002/kjm2.70307},
url = {https://onlinelibrary.wiley.com/doi/10.1002/kjm2.70307?af=R}
}